Brief: Vor Bio Reports First Quarter 2023 Financial Results And Provides Company Update
11/05/2023 21:51
Vor Biopharma Inc VOR.O :
* VOR BIO REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
PROVIDES COMPANY UPDATE
* VOR BIOPHARMA INC - NET LOSS FOR Q1 OF 2023 WAS $28.4
MILLION,
COMPARED TO $22.7 MILLION FOR Q1 OF 2022.
* VOR BIOPHARMA INC - CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES WERE $210.2 MILLION AS OF MARCH 31, PROJECTED TO FUND
OPERATIONS INTO Q1 OF 2025
* VOR BIOPHARMA INC - QTRLY LOSS PER SHARE $0.43
Source text for Eikon: ID:nGNX1HM2sr
Further company coverage: VOR.O
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning